Following the success of anti-CTLA-4 therapy, anti-tumor immunotherapy has been developed to target the programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) interaction. This evidence concerns the gene CD274 and neoplasm.